Financial information

BeiGene: Financial Information – Form 8-K

Financial information

BeiGene, Ltd. (the “Company”) previously submitted a registration request for a public offering of ordinary shares of the Company and the initial registration of these shares with the Scientific and Technological Innovation Council (the “STAR Market ) Of the Shanghai Stock Exchange (the “STAR Offer”), which has been prepared in accordance with the STAR Market Listing Rules and the applicable securities laws and regulations of the PRC (the “Securities Laws of the PRC ”). On July 28, 2021, the Company filed an application for registration for the STAR offering (the “Registration Application”) with the China Securities Regulatory Commission (the “CSRC”). On November 16, 2021, the CSRC accepted an updated prospectus filed by the Company (the “Prospectus”). The Prospectus is available to the public in Chinese only on the Shanghai Stock Exchange website at www.sse.com.cn.

As required by the securities laws of the PRC, the Prospectus contains historical financial information of the Company which has been prepared in accordance with China Enterprise Accounting Standards – Basic Standard (“CAS”) and others. accounting rules, guidelines and interpretations applicable in the PRC, including but not limited to the China Securities Regulatory Commission Compilation Rule for Disclosure of Information by Companies Offering Securities to the Public No.15 – General rules for financial statements (revised in 2014) and the compilation rule for the disclosure of information by companies offering securities to the public no. 24 – Special provisions on the disclosure of information in the financial statements of leading innovative pilot companies within the Sci-Tech Innovation Board (with CAS, “PRC GAAP”) for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021, certain historical financial results for the nine-month period ended September 30, 2021, and a forecast estimate of the preliminary range of certain expected financial results for the year ending December 31, 2021, which primarily include the total expected revenue and the net loss attributable to the Company (the “Estimated Range of Financial Results”). The main differences between this financial information prepared in accordance with PRC GAAP and that prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”), which were previously filed with the United States Securities and Exchange Commission (the “SEC”), were summarized in the company’s current report on Form 8-K filed with the SEC on June 30, 2021.

Research and development expenses allocated by key products and other R&D projects

As required by the securities laws of the PRC, the Prospectus contains financial information regarding research and development (“R&D”) expenses allocated by key products and other R&D projects, which have been prepared in accordance with to PRC GAAP. The corresponding financial information prepared in accordance with US GAAP is presented below. The amounts shown here are in thousands of US dollars.

Pipeline Products /
Projects

Semester ended June 30, 2021

Year ended
The 31st of December,
2020

Year ended
The 31st of December,
2019

Year ended
The 31st of December,
2018

Total

Implementation

Zanubrutinib

61,478

155,099

171,112

119,362

507,051

Clinical stage

Tislelizumab

92 740

232,369

191,992

127,129

644,230

Clinical stage

Pamiparib

6 966

28 156

41 938

38 325

115,385

Clinical stage

Other R&D projects

58,249

86,775

84 781

61 960

291 765

Clinical / preclinical stage

R&D collaboration projects

108 830

226,505

50,000

89,000

474 335

N / A

Sub-total of external R&D expenditure

328,263

728,904

539,823

435,776

2,032,766

Subtotal of internal R&D expenditure

348,554

565,973

387,515

243,229

1,545,271

Total

676,817

1,294,877

927 338

679,005

3,578,037

Range of financial results for the year ended December 31, 2021

As required by PRC securities laws, the prospectus contains an estimated range of financial results for the year ended December 31, 2021, which has been prepared in accordance with PRC GAAP. The corresponding financial information prepared in accordance with US GAAP is presented below. For the year ending December 31, 2021, total revenue is estimated to be between $ 1.059 billion and $ 1.239 billion, and the net loss attributable to the Company is estimated to be between $ 1.288 billion and $ 1.688 billion. The estimated range of financial results is based on the company’s preliminary calculation. The registered independent accountants of the Company have not audited, reviewed or performed any procedure relating to the estimated range of financial results and, therefore, do not express an opinion or any other form of assurance in this regard. The estimated range of financial results may change upon further examination and the actual results for the year ended December 31, 2021 may differ from the estimated range of financial results due to changes in underlying circumstances or events that cause assumptions and estimates to differ from current expectations.

Disclaimer

BeiGene Ltd. published this content on November 16, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on November 16, 2021 02:16:09 PM UTC.

Public now 2021

All news from BEIGENE, LTD.

Analyst Recommendations on BEIGENE, LTD.
Sales 2021 1,210 million

Net income 2021 -1 148 million

Net cash 2021 3,103 million

PER 2021 ratio -30.8x
Yield 2021
Capitalization 35,876 million
35,876 million
VE / Sales 2021 27.1x
VE / Sales 2022 24.1x
Number of employees 7600
Free float 67.7%

Duration :

Period:

Technical Analysis Chart of BeiGene, Ltd.  |  MarketScreener

Trends in Technical Analysis BEIGENE, LTD.

Short term Mid Road Long term
Tendencies Neutral Bullish Bullish

Evolution of the income statement

To sell

To buy

Average consensus TO BUY
Number of analysts 14
Last closing price

$ 382.37

Average price target

$ 432.32

Spread / Average target 13.1%


Source link